TwinBeech Capital’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$848K Buy
+25,100
New +$989K 0.2% 151
2025
Q2
– Sell
-102,036
Closed -$1.74M – 807
2025
Q1
$1.74M Buy
102,036
+89,347
+704% +$1.87M 0.03% 411
2024
Q4
$314K Buy
+12,689
New +$360K 0.01% 512
2024
Q3
– Sell
-30,859
Closed -$815K – 767
2024
Q2
$815K Buy
30,859
+23,458
+317% +$667K 0.02% 419
2024
Q1
$239K Buy
+7,401
New +$270K ﹤0.01% 494
2023
Q3
– Sell
-109,448
Closed -$2.08M – 759
2023
Q2
$2.08M Buy
+109,448
New +$2.04M 0.04% 374

Other funds holding IMVT

TwinBeech Capital's IMVT Position: Q3 2026 in Review

TwinBeech Capital opened a new position in Immunovant (IMVT) in Q3 2026: 25,100 shares worth $848K. The stake represents 0.2% of the portfolio and ranks #151 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in IMVT as recently as Q1 2025.

TwinBeech Capital first reported a position in IMVT in Q2 2023 and has held it in 6 quarters since. The position peaked at $2.08M in Q2 2023. 229 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • TwinBeech Capital held 25,100 shares of Immunovant worth $848K as of Q3 2026.
  • Immunovant was a new TwinBeech Capital position in Q3 2026.
  • Immunovant made up 0.2% of TwinBeech Capital's portfolio in Q3 2026, its #151 holding.
  • TwinBeech Capital first reported a position in Immunovant in Q2 2023 and has held it in 6 quarters since.
  • TwinBeech Capital's Immunovant position peaked at $2.08M in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.